Idera Pharmaceuticals, Inc. (IDRA) - Financial and Strategic SWOT Analysis Review by GlobalData

VIEWS: 13 PAGES: 44

More Info
									              Idera Pharmaceuticals, Inc. (IDRA) - Financial and Strategic SWOT
                                       Analysis Review
        Reference Code: GDPH59190FSA                                                                                          Publication Date: AUG 2012

          167 Sidney Street                                  Phone              +1 617 6795500                  Revenue          0.1 (million USD)
          Cambridge, MA                                      Fax                +1 617 6795592                  Net Profit       -23.78 (million USD)
          02139                                              Website            www.iderapharma.com             Employees        26
                                                                                                                                 Pharmaceuticals           &
          United States                                      Exchange           IDRA [NASDAQ]                   Industry
                                                                                                                                 Healthcare

       Company Overview
       Idera Pharmaceuticals, Inc. (Idera Pharmaceuticals) is a development stage biotechnology company. It focuses on the discovery
       and development of drug candidates for the treatment of infectious diseases, autoimmune and inflammatory diseases, cancer
       and respiratory diseases. It develops DNA and RNA based drug candidates that are targeted to Toll-Like Receptors (TLR) for
       treatment of infectious diseases and which can be used as vaccine adjuvants. The company designs and formulates proprietary
       TLR agonists and antagonists to modulate immune responses. Its product pipeline comprises IMO-2055, IMO-3100, IMO-8400,
       TLR 7, 8, and 9 agonists, IMO-4200 and IMO-2134.
       Key Executives                                                                SWOT Analysis
                      Name                                 Title                      Idera Pharmaceuticals, Inc., SWOT Analysis
         Sudhir Agrawal                      Chairman                                 Strengths                              Weaknesses
         Youssef El Zein                     Vice Chairman
                                                                                      Innovative Drug Development            Lack of Product Based
         Robert W. Karr, M.D.                Director                                 Technologies                           Revenues
         C. Keith Hartley                    Director
                                                                                      Strategic Alliances and                Dependence on Third Party
         William S. Reardon                  Director                                 Collaboration                          Manufacturers
        Source: Annual Report, Company Website, Primary and Secondary
        Research, GlobalData
                                                                                      Opportunities                          Threats
       Share Data
         Idera Pharmaceuticals, Inc.                                                  Product Pipeline                       Intense Competition
        Share Price (USD) as on 10-Aug-                                     1         Growth in the Prevalence of            Uncertainties from Clinical R&D
        2012                                                                          Cancer                                 Activities
        EPS (USD)                                                       -1.03
        Market Cap (million USD)                                           28        Source: Annual Report, Company Website, Primary and Secondary Research,
                                                                                     GlobalData
        Enterprise Value (million USD)                                     15
        Shares Outstanding (million)                                       28
       Source: Annual Report, Company Website, Primary and Secondary
       Research, GlobalData

       Financial Performance                                                         Recent Developments
                                                                                      Aug 09, 2012         Idera Pharma Reports Revenue Of $28,000 In
                                                                                                           Q2 2012
                                                                                      Jun 12, 2012         Idera Pharma Receives Nasdaq Listing Notice
                                                                                                           For Compliance With Minimum Market Value
                                                                                                           Requirement
                                                                                      May 09, 2012         Idera Pharma Reports Q1 2012 Results
                                                                                      Mar 14, 2012         Idera Pharma Reports Q4 2011 Results
                                                                                     Source: Annual Report, Company Website, Primary and Secondary Research,
                                                                                     GlobalData

       Source: Annual Report, Company Website, Primary and Secondary
       Research, GlobalData




Idera Pharmaceuticals, Inc. (IDRA) - Financial and Strategic SWOT                                                              Reference Code: GDPH59190FSA
Analysis Review
Source : www.globalcompanyintelligence.com                                                                                                                     Page 1
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
       Table of Contents
       Table of Contents ............................................................................................................................................................................... 2
          List of Tables .................................................................................................................................................................................. 4
          List of Figures ................................................................................................................................................................................. 4
       Section 1 - About the Company.......................................................................................................................................................... 5
       Idera Pharmaceuticals, Inc. - Key Facts ............................................................................................................................................. 5
       Idera Pharmaceuticals, Inc. - Key Employees .................................................................................................................................... 6
       Idera Pharmaceuticals, Inc. - Key Employee Biographies .................................................................................................................. 7
       Idera Pharmaceuticals, Inc. - Major Products and Services ............................................................................................................... 8
       Idera Pharmaceuticals, Inc. - Pharmaceutical Pipeline Products Data ............................................................................................... 9
          Idera Pharmaceuticals, Inc., Pipeline Products by Therapy Area ................................................................................................... 9
          Idera Pharmaceuticals, Inc., Pipeline Products by Development Phase ....................................................................................... 10
       Idera Pharmaceuticals, Inc. - History ................................................................................................................................................ 12
       Idera Pharmaceuticals, Inc. - Company Statement .......................................................................................................................... 14
       Idera Pharmaceuticals, Inc. - Locations And Subsidiaries ................................................................................................................ 15
          Head Office ................................................................................................................................................................................... 15
       Section 2 – Company Analysis ......................................................................................................................................................... 16
       Idera Pharmaceuticals, Inc. - Business Description ......................................................................................................................... 16
       Idera Pharmaceuticals, Inc. - SWOT Analysis .................................................................................................................................. 17
          SWOT Analysis - Overview........................................................................................................................................................... 17
          Idera Pharmaceuticals, Inc. - Strengths ........................................................................................................................................ 17
             Strength - Innovative Drug Development Technologies ............................................................................................................ 17
             Strength - Strategic Alliances and Collaboration ....................................................................................................................... 17
             Strength - Strong Patents Protection ......................................................................................................................................... 17
          Idera Pharmaceuticals, Inc. - Weaknesses ................................................................................................................................... 18
             Weakness - Lack of Product Based Revenues ......................................................................................................................... 18
             Weakness - Dependence on Third Party Manufacturers ........................................................................................................... 18
             Weakness - Discontinuations/Terminations .............................................................................................................................. 18
             Weakness - Termination of Agreement with Merck ................................................................................................................... 18
          Idera Pharmaceuticals, Inc. - Opportunities .................................................................................................................................. 18
             Opportunity - Product Pipeline .................................................................................................................................................. 18
             Opportunity - Growth in the Prevalence of Cancer .................................................................................................................... 19
             Opportunity - Changing Demographics ..................................................................................................................................... 19
          Idera Pharmaceuticals, Inc. - Threats ........................................................................................................................................... 19
             Threat - Intense Competition ..................................................................................................................................................... 19
             Threat - Uncertainties from Clinical R&D Activities.................................................................................................................... 20
             Threat - Product Liability Claims ............................................................................................................................................... 20
       Idera Pharmaceuticals, Inc. - Key Competitors ................................................................................................................................ 21
       Section 3 – Company Financial Ratios ............................................................................................................................................. 22
       Financial Ratios - Capital Market Ratios........................................................................................................................................... 22
       Financial Ratios - Annual Ratios ...................................................................................................................................................... 22
       Performance Chart ........................................................................................................................................................................... 24
       Financial Performance...................................................................................................................................................................... 24
       Financial Ratios - Interim Ratios....................................................................................................................................................... 25
       Financial Ratios - Ratio Charts ......................................................................................................................................................... 26
       Section 4 – Company’s Lifesciences Financial Deals and Alliances ................................................................................................ 27


Idera Pharmaceuticals, Inc. (IDRA) - Financial and Strategic SWOT                                                                                              Reference Code: GDPH59190FSA
Analysis Review
Source : www.globalcompanyintelligence.com                                                                                                                                                                Page 2
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
          Idera Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2006 to YTD 2012................................................. 27
          Idera Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2006 to YTD 2012 ................................................ 28
       Idera Pharmaceuticals, Inc., Recent Deals Summary ...................................................................................................................... 29
       Section 5 – Company’s Recent Developments ................................................................................................................................ 30
          Idera Pharmaceuticals, Inc., Recent Developments ..................................................................................................................... 30
             Aug 09, 2012: Idera Pharma Reports Revenue Of $28,000 In Q2 2012 ................................................................................... 30
             Jun 12, 2012: Idera Pharma Receives Nasdaq Listing Notice For Compliance With Minimum Market Value Requirement ..... 31
             May 09, 2012: Idera Pharma Reports Q1 2012 Results ............................................................................................................ 31
             Mar 14, 2012: I
								
To top